Sign in Subscribe
Stock exchanges

Armata Pharmaceuticals, Inc. Files Form 8-K Report Following Annual Meeting of Shareholders

Strategic Insights

— 2 min read

At its annual meeting held on June 12, 2025, shareholders of Armata Pharmaceuticals, Inc. elected seven new members to the company's board of directors, each for a one-year term expiring in 2026. The newly elected board members include Deborah L. Birx, M.D., Jules Haimovitz, Odysseas D. Kostas, M.D., Robin C. Kramer, Joseph M. Patti, Ph.D., Todd C. Peterson, Ph.D., and Sarah Schlesinger, M.D. The shareholders also approved, on a non-binding advisory basis, the compensation of the company's named executive officers, with 30,180,386 shares voting in favor and 75,804 shares voting against.

Key Takeaways:

  • The annual meeting of shareholders was held on June 12, 2025, where seven new members were elected to the board of directors.
  • Deborah L. Birx, M.D., Jules Haimovitz, Odysseas D. Kostas, M.D., Robin C. Kramer, Joseph M. Patti, Ph.D., Todd C. Peterson, Ph.D., and Sarah Schlesinger, M.D. were elected as new board members, each for a one-year term expiring in 2026.
  • The shareholders approved, on a non-binding advisory basis, the compensation of the company's named executive officers, with 30,180,386 shares voting in favor and 75,804 shares voting against.
  • The shareholders also ratified the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
  • The vote for the ratification of Ernst & Young LLP was 31,471,009 shares for and 0 shares against.
  • Broker non-votes were tallied for the approvals of the named executive officers' compensation and the appointment of Ernst & Young LLP, with 1,190,014 shares for each vote.
  • The company's board of directors is comprised of a diverse group of experts, with a mix of medical, scientific, and business backgrounds.

Statistics:

  • 30,188,915 shares voted in favor of Jules Haimovitz
  • 30,190,453 shares voted in favor of Odysseas D. Kostas, M.D.
  • 30,231,763 shares voted in favor of Robin C. Kramer
  • 30,231,464 shares voted in favor of Joseph M. Patti, Ph.D.
  • 30,228,440 shares voted in favor of Todd C. Peterson, Ph.D.
  • 30,149,529 shares voted in favor of Sarah Schlesinger, M.D.
  • 30,180,386 shares voted in favor of the compensation of the company's named executive officers
  • 75,804 shares voted against the compensation of the company's named executive officers
  • 31,471,009 shares voted in favor of the ratification of Ernst & Young LLP
  • 4,970 shares voted against the ratification of Ernst & Young LLP
  • 2,147 shares abstained from the ratification of Ernst & Young LLP

Sources:

  • UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 12, 2025
  • Armata Pharmaceuticals, Inc. 5005 McConnell Avenue Los Angeles, California 90066 (Address of principal executive offices)

Read more